Neutropenia

Hematology·MeSH: Neutropenia, Severe Congenital, Autosomal Recessive 3

Prevalence

0.5 / 100K

11 drugs in development·10 companies·2 clinical trials

Drug Pipeline by Phase

Approved(9)

Drug	Company
azacitidine	Amneal Pharmaceuticals, Inc. (AMRX)
cefepime	Seagen Inc. (SGEN)
cefepime	Atara Biotherapeutics, Inc. (ATRA)
fosinopril	Teva Pharmaceutical Industries Limited (TEVA)
fulphila	Mylan II B.V. (MYL)
nypozi	GT Biopharma, Inc. (GTBP)
rolvedon	SPECTRUM PHARMACEUTICALS INC (SPPI)
ROLVEDON	Assertio Holdings, Inc. (ASRT)
udenyca	Coherus Oncology, Inc. (CHRS)

Phase 3(2)

Drug	Company
peg-g-csf	TC BioPharm (Holdings) plc (TCBWF)
peg-g-csf injection (kexing biopharmaceutical co	TC BioPharm (Holdings) plc (TCBWF)

BioSniper tracks 11 drugs in development for Neutropenia across 10 companies.

There are 2 clinical trials targeting Neutropenia tracked by BioSniper.

The estimated prevalence of Neutropenia is approximately 0.5 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.